Data from recent clinical trials and basic research show a potential role for SGLT2 inhibitors in treating obesity-associated cardiometabolic complications targeting those abnormal pathophysiological systems in PCOS. This evidence concerns the gene SLC5A2 and polycystic ovary syndrome.